Other formats:
BibTeX
LaTeX
RIS
@article{819253,
author = {Dvořáková, Dana and Lengerová, Martina and Pospíšilová, Jana and Palásek, Ivo and Mayer, Jiří},
article_number = {23},
keywords = {acute myeloid leukemia;nucleophosmin;minimal residual disease},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations},
volume = {4},
year = {2009}
}
TY - JOUR
ID - 819253
AU - Dvořáková, Dana - Lengerová, Martina - Pospíšilová, Jana - Palásek, Ivo - Mayer, Jiří
PY - 2009
TI - A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations
JF - Leukemia
VL - 4
IS - 23
SP - 793-796
EP - 793-796
SN - 08876924
KW - acute myeloid leukemia;nucleophosmin;minimal residual disease
N2 - Acute myeloid leukemia (AML) is a heterogeneous group of diseases affecting hematopoietic stem cells. In recent years, several novel molecular abnormalities have been identified in patients with AML, particularly in cases with normal karyotype. Among these, mutations of the nucleophosmin gene (NPM1) have been established as currently the most common abnormality in AML, found about half of all AML patients with normal karyotype. For the detection of NPM1 mutations on the molecular level, several different assays have been described, including direct sequencing, fragment analysis or high resolution melt analysis or high-performance liquid chromatography. NPM1 mutations might be also suitable as target structure for minimal residual disease monitoring. Here, we describe a novel quantitative assessment based on allelic discrimination assays and real-time PCR with mutation-specific minor groove binding (MGB) probes. This method offers an alternative to the standard routine laboratory evaluation and representing an efficient approach to the specific detection of NPM1 mutations without any false positivities caused by amplification on the wild-type alleles.
ER -
DVOŘÁKOVÁ, Dana, Martina LENGEROVÁ, Jana POSPÍŠILOVÁ, Ivo PALÁSEK and Jiří MAYER. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations (A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.). \textit{Leukemia}. 2009, vol.~4, No~23, p.~793-796. ISSN~0887-6924.
|
